Hcw Biologics, Inc. (HCWB)
NASDAQ:HCWB
HCWB Stock Chart & Stats
$3.99
-$0.02(-4.12%)
At close: 4:00 PM EST
$3.99
-$0.02(-4.12%)
Day’s Range― - ―
52-Week Range$0.25 - $17.80
Previous CloseN/A
Volume102.01K
Average Volume (3M)16.73M
Market Cap
$1.80M
Enterprise Value$5.43M
Total Cash (Recent Filing)$1.95M
Total Debt (Recent Filing)$6.81M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding6,734,104
10 Day Avg. Volume977,640
30 Day Avg. Volume16,725,749
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.54
P/FCF Ratio-0.15
Enterprise Value/Market Cap3.01
Enterprise Value/Revenue100.18
Enterprise Value/Gross Profit-33.32
Enterprise Value/Ebitda-0.48
Forecast
1Y Price Target
$2.00Price Target Upside-49.87% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommendation for HCW Biologics Inc. is a 'Buy'.
Clinical DevelopmentHCW Biologics Inc. has selected a next-generation checkpoint candidate for clinical development.
Preclinical Study ResultsPreclinical studies of HCW11-040 have demonstrated an outperformance vs. pembrolizumab monotherapy in immune-cell activation and expansion, enhancement of immune-cell infiltration into the tumors, and immune-cell cytotoxicity against cancer cells.
Bears Say
Financial CommunicationHCW Biologics has received further communication from WY Biotech that it is not likely to meet the amended payment deadline.
HCW Biologics News
HCWB FAQ
What was Hcw Biologics, Inc.’s price range in the past 12 months?
Hcw Biologics, Inc. lowest stock price was $0.25 and its highest was $17.80 in the past 12 months.
What is Hcw Biologics, Inc.’s market cap?
Hcw Biologics, Inc.’s market cap is $1.80M.
When is Hcw Biologics, Inc.’s upcoming earnings report date?
Hcw Biologics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 32 days.
How were Hcw Biologics, Inc.’s earnings last quarter?
Hcw Biologics, Inc. released its earnings results on Mar 31, 2026. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.44 by -$0.58.
Is Hcw Biologics, Inc. overvalued?
According to Wall Street analysts Hcw Biologics, Inc.’s price is currently Overvalued.
Does Hcw Biologics, Inc. pay dividends?
Hcw Biologics, Inc. does not currently pay dividends.
What is Hcw Biologics, Inc.’s EPS estimate?
Hcw Biologics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hcw Biologics, Inc. have?
Hcw Biologics, Inc. has 6,734,104 shares outstanding.
What happened to Hcw Biologics, Inc.’s price movement after its last earnings report?
Hcw Biologics, Inc. reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.44. Following the earnings report the stock price went down -16.667%.
Which hedge fund is a major shareholder of Hcw Biologics, Inc.?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hcw Biologics, Inc.
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$2.00
▼(-49.87% Downside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
10.11% Insiders
0.38% Mutual Funds
6.04% Other Institutional Investors
83.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---